Maravai Lifesciences Holdings (MRVI) Long-Term Deferred Tax (2020 - 2023)

Maravai Lifesciences Holdings' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $773.7 million for Q3 2023.

• In Q3 2023, Long-Term Deferred Tax changed 0.33% year-over-year to $773.7 million; the TTM figure through Sep 2023 stood at $773.7 million (changed 0.33% YoY), while the FY2022 annual figure was $765.8 million, down 5.24% from the prior year.
• Long-Term Deferred Tax was $773.7 million for Q3 2023 at Maravai Lifesciences Holdings, up from $769.6 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $820.8 million in Q3 2021 to a low of $419.9 million in Q1 2021.
• Historically, Long-Term Deferred Tax has averaged $705.9 million across 4 years, with a median of $770.4 million in 2022.
• Biggest YoY gain for Long-Term Deferred Tax was 88.9% in 2022; the steepest drop was 6.05% in 2022.
• A 4-year view of Long-Term Deferred Tax shows it stood at $431.7 million in 2020, then jumped by 87.19% to $808.1 million in 2021, then decreased by 5.24% to $765.8 million in 2022, then grew by 1.03% to $773.7 million in 2023.
• The last three Long-Term Deferred Tax figures came in at $773.7 million (Q3 2023), $769.6 million (Q2 2023), and $767.0 million (Q1 2023), per Business Quant data.